Loading…
Swedish group that distributes and develops medical technology and diagnostics products, mainly through acquired niche companies.
Swedish group that distributes and develops medical technology and diagnostics products, mainly through acquired niche companies.
Grows mainly by buying small niche distributors and leaving them to run themselves, each earning a distribution margin on suppliers' products plus service, so group results track many local customer relationships rather than a few products.
In one line: A Nordic medtech distribution roll-up like a smaller Henry Schein.
Moat: narrow (distribution, customer qualification). Decentralized portfolio of niche distribution businesses with local customer relationships, but distribution has thin structural moats.
Headquarters: Stockholm, Sweden · Founded: 1990 · Employees: 2,295
Size AddLife (ALIF-B.ST) is a Sweden Health Care company (Medical/Nursing Services) with a market value of $2.29B, the 75th largest of 221 Sweden companies the cockpit tracks. Shares closed at SEK 184.10 on 6 Nov 2026.
Performance Over six months the shares gained 25.4%, against +24.9% for the median peer and +8.2% for the Sweden market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 1.6% over the last twelve months (peer median +6.1%); the operating margin is 7.7% (peer median 7.8%).
Valuation It trades at 40.5× forward earnings against a peer median of 40.1× (8th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 22% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.3 points below its cost of capital (9.5% WACC).
Next results Next results expected around 3 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | SEK 10.7B | SEK 10.4B | SEK 10.3B | SEK 9.69B | SEK 9.08B |
| Revenue growth | — | +2% | +6% | +7% | — |
| Gross profit | SEK 4.14B | SEK 3.27B | SEK 3.14B | SEK 2.77B | SEK 2.78B |
| EBITDA | SEK 1.63B | SEK 1.61B | SEK 1.53B | SEK 1.46B | SEK 1.45B |
| Net income | SEK 644M | SEK 560M | SEK 252M | SEK 190M | SEK 480M |
| Free cash flow | SEK 1.13B | SEK 1.15B | SEK 845M | SEK 547M | SEK 696M |
| Capital expenditure | SEK 309M | SEK 284M | SEK 297M | SEK 308M | SEK 282M |
| Total debt | SEK 5.14B | SEK 4.77B | SEK 5.07B | SEK 5.29B | SEK 5.59B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| AddLife ALIF-B.ST | $2.29B | +25% | +2% | 8% | 40.5× | 21.6% |
| Henry Schein HSIC | $9.51B | +22% | +6% | 6% | 14.8× | 9.8% |
| Asker Healthcare ASKER.ST | $2.98B | -5% | +12% | 7% | 26.6× | 1.2% |
| Avantor AVTR | $10.5B | +86% | +1% | 8% | 17.7× | 16.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ALIF-B.ST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +10.2% | +8.4% | 6th highest of 21 |
| 6-month return | +25.4% | +24.9% | 10th highest of 20 |
| Distance from 52-week high | -7.0% | -16.0% | 4th highest of 21 |
| Revenue growth (TTM) | +1.6% | +6.1% | 8th lowest of 21 |
| Operating margin | 7.7% | 7.8% | 11th highest of 21 |
| Forward P/E | 40.5× | 40.1× | 8th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 21.6% | 10.0% | 5th most demanding of 15 |
| Growth delivered (Del g) | +14.6% | +8.7% | 5th highest of 15 |
| Hurdle (Req g minus delivered) | +7.0 pp | +3.3 pp | 7th most demanding of 15 |
| ROIC minus cost of capital | -3.3 pp | -1.1 pp | 9th lowest of 20 |
| EV / EBITDA | 16.6× | 12.5× | 5th most expensive of 12 |
| Net debt / EBITDA | 2.9× | 1.0× | 7th most indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| AddLife ALIF-B.ST | Sweden | $2.29B | +25% | +2% | 8% | 40.5× | 21.6% | +14.6% |
| Addus HomeCare ADUS | United States | $2.32B | +25% | +12% | 11% | 16.6× | 4.9% | +13.2% |
| NeoGenomics NEO | United States | $2.18B | +88% | +11% | -6% | 58.9× | n/a | n/a |
| Pediatrix Medical MD | United States | $2.44B | +33% | +2% | 12% | 12.9× | -4.5% | +2.0% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.99B | +5% | -3% | 7% | 31.7× | 6.7% | -6.1% |
| Dian Diagnostics 300244.SZ | China | $1.97B | +11% | -5% | 9% | 25.2× | 2.4% | -1.1% |
| Emeis EMEIS.PA | France | $1.94B | -30% | +4% | 3% | n/a | 21.3% | +8.5% |
| agilon health AGL | United States | $1.90B | +109% | 0% | -4% | 67.5× | n/a | n/a |
| GeneDx WGS | United States | $1.86B | +53% | +25% | -12% | 98.7× | n/a | n/a |
| Aveanna Healthcare AVAH | United States | $2.89B | +97% | +20% | 11% | 15.4× | 13.4% | +10.2% |
| Meinian Onehealth Healthcare 002044.SZ | China | $2.89B | -9% | -4% | 9% | 55.1× | 5.8% | +5.7% |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.74B | +15% | +22% | 15% | 89.1× | 41.9% | +26.9% |
| Azenta AZTA | United States | $1.72B | +104% | +1% | -3% | 103.7× | 56.0% | +8.9% |
| Personalis PSNL | United States | $1.71B | +164% | -13% | -164% | n/a | n/a | n/a |
| Fameglow 3774.HK | Hong Kong | $3.19B | n/a | +36% | 11% | n/a | 48.8% | +48.4% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.63B | -47% | +8% | 3% | 40.1× | 15.0% | -5.1% |
| Ambea AMBEA.ST | Sweden | $1.63B | +30% | +13% | 8% | 15.8× | 1.7% | +7.7% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.60B | +22% | +24% | 32% | 64.3× | 39.3% | +16.7% |
| Teladoc Health TDOC | United States | $1.60B | +21% | -2% | -5% | n/a | -5.2% | +18.3% |
| Sonida Senior Living SNDA | United States | $1.58B | -14% | +49% | -11% | n/a | n/a | n/a |
| Acadia Healthcare ACHC | United States | $3.44B | +47% | +4% | 10% | 18.7× | n/a | n/a |